



BioPharmica Limited

8 April 2008

Companies Announcements Office
Australian Securities Exchange Limited
10th Floor, 20 Bond Street
SYDNEY NSW 2000

BioPharmica [ASX:BPH] ASX Release

FUJIKURA AND BIOPHARMICA SIGN COLLABORATION AGREEMENT

BioPharmica Limited (BPH) has signed a collaboration agreement in Tokyo with leading international electronics and telecommunications manufacturing group Fujikura Limited. The collaboration includes Swinburne University of Technology (SUT), BioPharmica and Fujikura. The signing of the collaborative agreement is to facilitate production of the fibreoptic nanoprobe, the core technology of the BPH/SUT joint venture developing surface-enhanced raman spectroscopy (SERS) for biosensing and other applications. SUT will process and test pre-form samples delivered by Fujikura in order to determine the best manufacturing procedure. SUT will then deliver a report to Fujikura describing the method used for routine manufacture and commercial scale-up with the objective of Fujikura becoming the manufacturer and possible global product distributor and licensee.

Since its establishment in 1885, Fujikura Ltd. has become one of Japan's foremost manufacturers of electric wire and cabling solutions, and leads the world in optical fibre and network manufacturing technology. Fujikura's worldwide network consists of locations throughout America, Asia, China, the Middle East, Europe and Japan. Fujikura employs over 43,000 people with sales in 2007 of over US\$5billion. The company's products include optical fibres and optical components, electronic materials and multi-layer and fine pitch flexible printed circuits, wiring technologies and cables for the telecommunication, automotive, HV transmission and electronics industries. Fujikura drives its expansion through a substantial commitment to research and development.

SUT in collaboration with BPH have been working to develop and commercialise the SERS nanoprobe, a solid-state component comprising the microscopic tip of an optical fibre for use in biosensing. This sensor is designed to be incorporated into portable field instruments with potential in medical, military and environmental applications. BPH has been collaborating with SUT since 2004 to develop and commercialise the SERS nanoprobe and has a 52% interest in the technology.

Dr Paul Stoddart from Swinburne University of Technology, a Research Fellow at the Centre for Atom Optics and Ultrafast Spectroscopy has developed the proprietary nanostructured fibre optic sensors which will be both inexpensive and offer enhanced sensitivity. The collaboration agreement with Fujikura is to address the limited availability of the nanoprobe and develop processes to enable their high volume manufacture.

Yours faithfully,

David Breeze
Executive Director

About BioPharmica Limited

BioPharmica [ASX: BPH] is an Australian Stock Exchange listed company developing biomedical research with academic and hospital institutes. The Company provides early stage funding for a direct collaboration, a spin out company or to secure a license. BioPharmica provides assistance with product development, funding and commercial strategies, whilst the institutional partner provides a majority of the infrastructure and research expertise.